Worm.com

Guide to Spyware and AntiVirus Information

You are currently browsing the Worm.com weblog archives for the day Thursday, September 27th, 2007.

 

September 2007
M T W T F S S
« Aug   Oct »
 12
3456789
10111213141516
17181920212223
24252627282930

Sponsors

Archive for September 27th, 2007

MessageLabs, the leading provider
of integrated messaging and web security services to businesses worldwide,
today announced the results of its MessageLabs Intelligence Report for
September and 3rd quarter of 2007. The new data reveals that virus and
phishing levels have significantly increased, reaching levels not seen
since early 2006. In addition, MessageLabs exposes a second wave of highly
targeted C-level and senior management email attacks with increased
sophistication and outreach.

With a virus threat now incorporated within every 48 emails,
cyber-criminals are steering away from using the more obvious attachment
method of distribution and favoring the use of links to malicious websites
hosting malware code. This technique, which increased in popularity by
approximately 15 percent this quarter, enables social engineering-based
attacks such as e-postcards to be utilized.

Mirroring the recent resurgence in virus attacks, the volume of phishing
threats has also reached exponential levels this month with every 87 emails
comprising of a phishing attack. Through the increased availability of
phishing kits and the uptake of aggressive phishing techniques such as
‘rock’ phishing, the quantity and severity of these attacks are able to
increase dramatically. ‘Rock’ phishing utilizes a phishing kit, which
enables a single compromised computer within a botnet to host multiple
phishing sites at the same time.

“The start of the new school year seemed to bring back an increase in
old-school threats and in high volumes. With email more ubiquitous than the
telephone and one in 48 emails containing a virus, most people are
unwittingly receiving more than one virus a day,” said Mark Sunner, Chief
Security Analyst, MessageLabs. “As we enter the last quarter of 2007 and
draw closer to the holiday season, the bad guys will be provided
opportunity to disguise their attacks through the increase in genuine
well-wishing emails and the anticipated upsurge in online shopping traffic.
In addition, with the incessant rise of comprised machines through
aggressive botnet activity, further spam level increases are anticipated.”

September is not just the month of mass-outreach attacks — the highly
targeted approach is still rife. On September 12, more than 1,100 C-level
and senior management executives became the target of another attack,
thought to be from the same perpetrators of the June 26 C-level assault.
With increased sophistication, the emails, which purport to be from a
recruitment company, use a Microsoft error message to persuade the victims
to click on the RFT attachment. Once opened, the RFT file contains an
executable, which drops two files onto the computer which in turn will be
used to pass sensitive information back to the attacker.

Other report highlights:

Web Security: Analysis shows that 73.8 percent of the malware intercepted
in September was new. Analysis of policy-based traffic highlighted that
corporate tolerance of social networking sites is diminishing with Facebook
being the most blocked site within the Personal’s and Dating category for
SMBs and Friends Reunited top of the same category for the Enterprise.

Spam: In September, the global ratio of spam in email traffic from new and
unknown bad sources, for which the recipient addresses were deemed valid,
was 73.5 percent, a decrease of 0.5 percent on the previous month. When
reviewing the overall spam rates on a quarterly basis, a drop of 0.9
percent was observed since Q2 2007.

Viruses: This month, the global ratio of viruses in email traffic from new
and previously unknown bad sources destined for valid recipients was 1 in
48.8 emails (2.05 percent), an increase of 0.8 percent since last month.
Virus and trojan levels have declined steadily since 2006, with the Q3 2007
rates of 1 in 67.2 emails being the highest quarterly level since Q2 2006.

Phishing: With an increase of 0.6 percent, one in 87.2 emails is comprised
of some form of phishing attack in September, the highest level to date.
When judged as a proportion of all email-borne threats such as viruses and
trojans, the number of phishing emails has risen by 9.7 percent to 56.0
percent of the malware threats intercepted in September. Over the last
quarter, phishing rates have increased from 1 in 232.0 to 1 in 124.3.

Geographical Trends:

--  Israel continued to have the highest spam rate this month with 73.8
    percent. Hong Kong was the second most highly spammed country registering a
    6.6 percent increase in spam since August.
--  Japan had the lowest spam rate with 27.1 percent. Germany also saw a
    sharp decrease of 10.2 percent in spam rates in the last month, marking a
    quarterly decline of 6.63 percent
--  India still remains the region most affected by viruses with 1 in 53
    emails containing a virus. The largest rise in virus activity was observed
    in the Netherlands where levels rose by 0.2 percent, from 1 in 750.1 emails
    in August to 1 in 303.3 emails in September.
    

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

DUBLIN, Ireland — Research and Markets (http://www.researchandmarkets.com/reports/c69681) has announced the addition of "Stakeholder Opinions: Respiratory Syncytial Virus (RSV) - A Market Yet to Reach its Full Potential" to their offering.

RSV mostly causes upper respiratory tract infections (URTI), resulting in the common cold. However, in certain risk groups, RSV can cause more severe lower respiratory tract infections (LRTI) leading to bronchiolitis. These risk groups include elderly people, patients with underlying pulmonary or cardiac disease, premature infants, children under four years old and immunocompromised patients.

Scope of this title:

* Discusses disease background, providing insight in RSV epidemiology, etiology and symptoms

* Gives a breakdown of RSV (hospitalization) prevalence in the seven major markets

* Examines current diagnosis and treatment trends, providing physicians opinions

* Examines the RSV pipeline by type treatment, prophylaxis and vaccines, including a short discussion of each pipeline product

Highlights of this title:

* Some physicians do not value the importance of a correct RSV diagnosis, since there is no effective treatment available. Furthermore, the American Academy of Pediatrics does not recommend routine testing for RSV in bronchiolitis. However, there are reasons why proper diagnosis should be considered, and there is a range of tests available for that.

* The RSV market is currently dominated by MedImmunes Synagis, a prophylactic monoclonal antibody. As RespiGams successor, Synagis was first launched in 1998 and now has sales of around $750 million per RSV season. Due to its high costs though, Synagis is only prescribed to a very limited group of individuals.

* Although the most important unmet need in RSV is an effective treatment or vaccine, many companies have discontinued their developments in this field. Only two companies have an RSV treatment in clinical development (Novartis/Arrow Therapeutics and Alnylam) and MedImmune dominates the limited vaccine development.

Reasons to order your copy:

* Gain insight into the issues of current diagnosis and treatment for RSV through key opinion leader comments

* Review the unmet needs and the clinical and commercial factors driving new product decisions

* Identify the opportunities and threats presented by the RSV pipeline and predict the future shape of the market

Report Breakdown

Chapter 1 - Executive Summary
Chapter 2 - Disease Background
Chapter 3 - Diagnosis
Chapter 4 - Current Treatment And Prevention Option
Chapter 5 - Future Trends

 Appendix A - Bibliography
 Appendix B - Commercially Available Antigen Detection Assays

For more information visit http://www.researchandmarkets.com/reports/c69681

Source: Datamonitor

COPYRIGHT 2007 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis

Dutch biotechnology
company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX)
today announced the discovery of a set of human monoclonal antibodies
against H5N1. These results, demonstrating the potential of human
monoclonal antibodies for pandemic preparedness, were presented today
at the 5th International Bird Flu Summit held in Las Vegas, Nevada.

A total of twenty one human monoclonal antibodies were discovered.
These were found to be able to neutralize the H5N1 virus of avian
influenza, which currently presents a global threat. The most potent
of the antibodies was shown to neutralize the broadest range of H5N1
strains that have emerged between 1997 and 2004. This antibody may
therefore provide a powerful tool in pandemic preparedness. In
addition, this antibody prevents flu, in pre-clinical models, when
given twenty four hours before a challenge with a lethal dose of
highly pathogenic H5N1 virus. When given three days after infection,
it also was shown to prevent death and cure the disease.

“Our discovery of potent human monoclonal antibodies against a number
of different H5N1 pandemic flu types, provide proof of concept that
antibodies are a serious alternative to vaccination or antiviral
treatment”, said Dr. Jaap Goudsmit, Chief Scientific Officer of
Crucell. “What is most encouraging is the fact that these antibodies
are not only able to prevent infection, but also open the possibility
to treat infected individuals. Treatment with this antibody provides
an instantaneous antiviral response, which is an advantage over the
delayed immune response after (prepandemic) vaccination.”

The set of monoclonal antibodies, which was produced by Crucell
researchers using phage display and Crucell PER.C6® technology,
showed the potential to neutralize distinct H5N1 viruses,
A/Vietnam/11994/04, A/Hong Kong/213/03 and A/Hong Kong/156/97. The
antibodies apparently recognize a part of the viral membrane protein
that is present among all H5N1 viruses tested. The most potent
neutralizing antibody was tested in pre-clinical models for the
ability to protect against infection with the highly pathogenic
A/Hong Kong/97 H5N1 virus and was also tested for its ability to stop
the development of the disease caused by this virus. When the
monoclonal antibody was given in a pre-clinical model, one day prior
to infection with the H5N1 virus, it resulted in full protection
against infection. Treatment with the antibody up to three days after
infection, resulted in 100% survival and cure of the disease.

About Pandemic Influenza

Influenza is a highly infectious virus which spreads easily from
person to person. In a pandemic, a new and more virulent virus
infectious for humans arises with the potential to cause severe
disease and high mortality. H5N1 Viruses isolated from wild and
domestic birds and from humans since the outbreaks in Hong Kong
separate in distinct genetic groups (clade and subclades) of closely
related viruses. Clade 1 virus circulated in Cambodia, Thailand and
Viet Nam and caused infections in humans in 2004 and 2005. Clade 2
viruses circulated in China and Indonesia in 2003 -2004 and spread to
the Middle East, Africa and Europe in 2005 and 2006.

About Crucell

Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a
biotechnology company focused on research, development and worldwide
marketing of vaccines and antibodies that prevent and treat
infectious diseases. Its vaccines are sold in public and private
markets worldwide. Crucell’s core portfolio includes a vaccine
against hepatitis B, a fully-liquid vaccine against five important
childhood diseases, and a virosome-adjuvanted vaccine against
influenza. Crucell also markets travel vaccines, such as the only
oral anti-typhoid vaccine, an oral cholera vaccine and the only
aluminium-free hepatitis A vaccine on the market. The Company has a
broad development pipeline, with several Crucell products based on
its unique PER.C6® production technology. The Company licenses this
and other technologies to the biopharmaceutical industry. Important
partners and licensees include DSM Biologics, sanofi aventis, GSK and
Merck & Co. Crucell is headquartered in Leiden (the Netherlands),
with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the
US. The Company employs over a 1000 people. For more information,
please visit www.crucell.com .

Forward-looking statements

This press release contains forward-looking statements that involve
inherent risks and uncertainties. We have identified certain
important factors that may cause actual results to differ materially
from those contained in such forward-looking statements. For
information relating to these factors please refer to our Form 20-F,
as filed with the U.S. Securities and Exchange Commission on June 13,
2007, and the section entitled “Risk Factors”. The Company prepares
its financial statements under generally accepted accounting
principles in the United States (US GAAP) and Europe (IFRS).

Information provided by: Findarticles.com

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google
  • Reddit
  • Slashdot
  • Spurl
  • Technorati
  • TwitThis